Nunapsians

Leadership

Staff

NUNAPS

To contribute to the brain health of humans

with unwavering adventure and passion

Why we are here

"우리는 몸이 아플 때 의사를 찾아가 약이나 주사를 처방 받습니다.

그런데 머지 않은 미래에 게임이나 앱, 소프트웨어, VR로

질병을 예방하고 치료하는 시대가 옵니다.

디지털 콘텐츠가 약이 되는 시대! 그 선두에 뉴냅스가 있습니다.

뉴냅스는 서울아산병원 신경과 강동화 교수가 스핀오프한

neuroscience 기반 소프트웨어 개발 회사로

국내 최초로 디지털 치료제 식약처 허가 임상시험을 진행 중입니다.

디지털 치료제는 엄격한 치료 효과 검증을 거쳐 의학적 치료를

제공하는 고품질 소프트웨어로서, 화학물, 유전자 치료제에 이어

제3세대 신약으로 불립니다.

우리가 만든 소프트웨어가 누군가의 질병을 치료하는 세상을 꿈꾸며

가슴 뛰는 사람들이 여기 뉴냅스에 모여 있습니다."

We are building a platform to identify target biomarkers and develop new digital therapeutics to treat or manage various neurological disorders.

We have initiated a pivotal clinical trial of our first product, Nunap Vision, which provides visual perceptual training to treat visual field defects caused by brain damage. It is the first digital therapeutics clinical trial approved by MFDS (formerly known as KFDA) in South Korea.

Nunap Vision is a SaMD (Software as a Medical Device) utilizing HMD VR. While its clinical efficacy has already been demonstrated in previous proof-of-concept studies, we designed the pivotal clinical trial to be multi-center, double-blind, randomized, and placebo-controlled for further validation.

We take pride in our in-house convergence medical and tech professionals comprised of neurologists, software and game/VR developers, engineers, AI scientists, perceptual psychologists, and mathematicians. It enables us bring neuroscience, medicine and IT together to change how medicine is designed and delivered. We plan to develop pipelines for various brain disorders to become a leading digital therapeutics platform company in the future.